1 Introduction

1.1 Developing a New Medicine

1.2 Key Risks at the Candidate Selection Stage

1.3 Attrition in the Pharmaceutical Industry

1.4 Evolution of the Pharma R&D Over the Last Two Decades

1.5 Pharma R&D Productivity in Decline

1.6 Cost of Pharma R&D and Cost Up to Candidate Selection

1.7 Increased Risks in Developing a Topical Drug

1.8 Increased Opportunities to Develop a Topical Drug

References

2 Choosing Topical Drug Candidate: Historical Overview

2.1 The Pragmatic Topical Drug Development Approach: An Existing Oral/Systemic Drug is Further Developed as a Topical

2.1.1 Local Anaesthetics (<1900)

2.1.2 Corticosteroids (1952)

2.1.3 Retinoids (1962)

2.1.4 Antifungals (1967)

2.1.5 NSAIDS (1971)

2.1.6 Antivirals (1983)

2.1.7 Vitamin D3 Derivatives (Late 1980s)

2.1.8 Immunosuppressors (1992)

2.1.9 Summary

2.2 Moving towards Improved Topical Drug Candidate Selection Processes: Use of In Vivo Models

2.2.1 The Particular Case of Corticosteroids: Use of Human Models (Early 1960s)

2.2.2 Topical Rodent Models (1960s)
2.2.3 Combined Use of Topical Models and Systemic Rodent Models (1980s) ....................................................... 22
2.2.4 Use of Topical Pig Models (1990s) ..................................... 22
2.3 Historical Topical Drug Candidate Selection Summary ................. 24
References ................................................................................................ 25

3 Key Factors Affecting the Efficacy of a Topical Drug Candidate: Learnings from Past Topical Drug Development ................................ 29
3.1 Skin Barrier Condition vs. “Easiness” of Topical Drug Development........................................... 29
3.1.1 Skin and Its Barrier ........................................................................ 29
3.1.2 Skin Disease, Target Site in Skin and Skin Barrier Properties ........................................................................ 30
3.1.3 Success Rate of First in Class Topical Drugs ..................................... 31
3.1.4 Summary of Impact of Skin Disease, Its Target Site, Its Barrier and Success Rate of Topical Drug Development ............................................. 32
3.2 Drug Potency and Clinical Efficacy ..................................................................................... 34
References ................................................................................................ 35

4 Topical Versus Oral/Systemic Drug Discovery .................................... 39
4.1 Drug Discovery Evolution ........................................................................ 39
4.2 Oral/Systemic Drug Discovery ...................................................................... 40
4.3 Topical Drug Discovery .............................................................................. 41
4.4 Two Key Differences in Discharging Risk in Between the Oral/Systemic and Topical Drug Discovery Processes ............. 43
4.4.1 Defining Target Tissue (Skin) Concentration ...................................... 43
4.4.2 Checking that Pharmacokinetic Parameters Are Appropriate............................................................................... 44
4.5 Consequences for Preclinical Stage: “Maximising Percutaneous Flux” ................................................ 46
4.6 Learnings from the Oral Drug Development Process ................................................. 47
References ................................................................................................ 47

5 Assessing Drug Concentration in Skin: Direct and Indirect Methods ............................................................................. 49
5.1 Direct Methods ......................................................................................... 49
5.1.1 Tape Stripping (Vitro/Vivo) ................................................................... 49
5.1.2 Skin Biopsy ........................................................................................ 51
5.1.3 In Vitro Percutaneous Studies: Skin Tissue Concentration ......................... 52
5.1.4 Suction Blister ........................................................................................ 53
5.1.5 Skin Surface Contamination Issue ......................................................... 54
5.2 Indirect Methods ..................................................................................... 58
5.2.1 Introduction .......................................................................................... 58
5.2.2 Plasma Collection .................................................................................. 58
5.2.3 Microdialysis ................................................................. 59
5.2.4 In Vitro Percutaneous Studies: Percutaneous Flux ............. 61

5.3 Potential Use of the Skin PharmacoKinetic Sampling
Methods, Comparisons of Methods and Consequences ............. 61
5.4 Using Percutaneous Flux or Plasma Concentration as Surrogate
Measurement of Skin Concentration ....................................... 63
References ............................................................................ 66

6 Assessing Topical Efficacy ....................................................... 69
6.1 Assessing Efficacy and Dose Prediction for a Systemic
Target .................................................................................... 69
6.2 PharmacoDynamic Models .................................................. 70
  6.2.1 Rodents ........................................................................... 70
  6.2.2 Minipigs ......................................................................... 71
  6.2.3 Human Microplaque Assay ........................................... 72
  6.2.4 In Vitro PharmacoDynamic Models ............................... 73
  6.2.5 “In Silico” PK/PD Approaches ................................... 74
6.3 Conclusion ............................................................................ 82
References ............................................................................ 83

7 Assessing Therapeutic Index ...................................................... 87
7.1 Introduction .......................................................................... 87
7.2 A “Crude” Approach: Comparing the Mass of Target
Tissue with Total Body Mass ................................................ 88
7.3 Calculated Approach ............................................................ 89
7.4 Comparative Approach ....................................................... 91
References ............................................................................ 93

8 Topical Vehicle Selection: Myths and Reality .......................... 95
8.1 Introduction .......................................................................... 95
8.2 Skin Penetration Enhancement .......................................... 96
8.3 Retention in Skin ............................................................... 97
8.4 For Each Compound, A Specific Formulation: A Must? ........... 99
8.5 Vehicle Aesthetics .............................................................. 101
8.6 Drug Formulated as a Dispersion or as a Solution? ............... 105
8.7 Conclusion ........................................................................... 105
References ........................................................................... 106

9 Dermal Drug Development Strategies ..................................... 109
9.1 Option#1: Clinical Molecule Repurposing—Developed
Drug for a Non Systemic Indication on a New Target Class ....... 109
9.2 Option#2: Full Lead Optimization—New Drug from
a New Mechanism of Action for a Topical Application ............. 111
9.3 Option#3: “Me Better”—Improved Drug for a Known
Topical Target Class ................................................................ 111
References ........................................................................... 111
9.4 Option#4: Chemical Series Repurposing—Advanced Lead Optimized Chemicals Series Screened Against for a Topical Indication ................................................................. 112 Reference ................................................................................................ 113

10 Topical Drug Candidate Selection Criteria and Cascade .................. 115
10.1 General Principles: Discharging Risk ....................................... 115
10.2 Medicinal Chemistry and Chemical Space ................................ 116
10.3 Potency .............................................................................. 117
10.4 Percutaneous Flux .................................................................. 118
10.5 Pharmacological Kinetics Response ........................................ 122
10.6 Preclinical Proof of Concept ................................................. 123
10.7 Solution Stability—Water Stability ...................................... 123
10.8 UV Absorption ..................................................................... 124
10.9 Local Irritation ...................................................................... 125
10.10 Systemic Effect (Clearance & Protein Binding) ....................... 125
10.11 Other Criteria Not that Important for a Topical Candidate ........ 125
10.11.1 Skin Metabolism ............................................................. 125
10.11.2 CYP 450 Inhibition/Induction and Drug Drug Interaction ............... 126
10.12 Comparison of the Criteria Used to Select an Oral/Systemic Candidate and a Topical One ......................... 126
10.13 Example of Candidate Selection Cascade When Repurposing a Whole Chemical Series ...................... 128 References ................................................................................................. 130

11 Selecting Dermal Drug Candidate: Some Useful Quotations and “Rules” ................................................................. 133
11.1 “Manage Every One’s Expectation on Chance of Success… Even If Skin Is Thin and the Target Site Less than 1 mm Down, Delivering through the Topical Route Is Challenging” ................................................................. 133
11.2 “Don’t Believe the Molecule You Have Developed for a Systemic Route Is the Best One You Have from Your Lead Optimisation Effort… Look for a Better One” ................................. 134
11.3 “Don’t Be Scared of the Systemic Toxicological Findings Associated with the Target… It Is Most of the Time Not of Concern and Manageable” ................................................................. 134
11.4 “Expect a Substantial Toxcological Package to Develop a Topical NCE and a Long Development Time” ..................................................................... 134
11.5 “Prefer Minipig to Rodent for the Toxicological Package If You Don’t Want to Stop Your Asset for a Wrong Reason: Exacerbated Local Tox that Would Not Translate in Human” ..................................................................... 135
11.6 “For an In Vitro Skin Permeation, If Substantial Concentration Appears to Have Been Achieved in Skin While Nothing Is Found in the Receiving Fluid, this Is Bad News Not Good News” .................................................. 135
11.7 “Don’t Believe in Compound Retention in the Viable Epidermis or Dermis” ................................................................. 135
11.8 “Don’t Expect Miracles from the Formulation in Terms of Drug Delivery” ............................................................. 135
11.9 “Don’t Go with Fancy “Gunky” Vehicle… Think of the Patients and the Aesthetics Required for a Topical” ............ 136
11.10 “Don’t Expect a Large Molecule to Cross the Stratum Corneum” ................................................................ 136
11.11 “If Possible, Chose a Candidate Molecule with a Long Skin Crossing Time” ................................................. 137
11.12 “Put a Relevant Screening Cascade: Discharge Early the Key Risks of a Topical Drug… Delay the Other Data” ........ 137
11.13 “Deeper the Target the More Difficult to Engage the Target” ................................................................................. 137
11.14 “Think ‘Ligand Efficiency’ as a Way to Improve the ‘Compound Topical Power’” ............................................. 138

12 Conclusions and Perspectives ................................................................. 139
Reference ................................................................................................. 143

Index ........................................................................................................... 145
Dermal Drug Selection and Development
An Industrial Perspective
Trottet, L.; Maibach, H.
2017, XVI, 148 p. 53 illus., 35 illus. in color., Hardcover
ISBN: 978-3-319-59503-0